Premium
High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates
Author(s) -
Khashei Reza,
Dara Mahintaj,
Bazargani Abdollah,
Bagheri Lankarani Kamran,
Taghavi Alireza,
Moeini Maryam,
Dehghani Behzad,
Sohrabi Maryam
Publication year - 2016
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12567
Subject(s) - clarithromycin , helicobacter pylori , 23s ribosomal rna , point mutation , restriction fragment length polymorphism , microbiology and biotechnology , polymerase chain reaction , biology , drug resistance , helicobacter , mutation , gene , genetics , ribosome , rna
This study aimed to investigate the clarithromycin resistance and its associated molecular mechanisms among Helicobacter pylori isolates from dyspeptic patients in Shiraz, Iran. From January to May 2014, 100 H. pylori strains were isolated from patients with gastroduodenal disorders. The resistance to clarithromycin was quantitatively evaluated, using Epsilometer (E‐test) method. Polymerase chain reaction‐restriction fragment length polymorphism ( PCR ‐ RFLP ) was performed on all the isolates to detect A2143G and A2142G mutations in 23S rRNA gene. The H. pylori isolation rate was found to be 31.4%. E‐test showed that 20% of isolates were resistant to clarithromycin ( MIC ≥ 1 mg/L). MIC of clarithromycin ranged between 0.016 and 24 mg/L. Findings of PCR ‐ RFLP showed that the A2142G was the most (90%) frequently point mutation, followed by the A2143G (10%). No statistically significant difference was found between H. pylori clarithromycin resistance point mutations and patients’ gender or age. To the best of our knowledge, this is the first report of high frequency of A2142G point mutation in Iran and probably in other regions of the world. Considering the increasing trend of H. pylori resistance to clarithromycin due to these mutations, it is crucial to investigate the new therapeutic approaches against H. pylori infection.